3 reasons SAVA is a 100Xer
Join the Small Caps Newsletter for early access to reports on two new small caps each month, plus the Discord and Book “Guide to Crushing the Market”:
https://tendiesclub.substack.com/welcome
Sign, Comment, and Share the Petition to Get Simufilam to Alzheimer’s Patients:
https://www.change.org/p/bring-simufilam-to-alzheimer-s-patients-as-soon-as-possible
Videos are not financial advice
00:00 Intro
02:51 SAVA Hero Paul Efron Makes the News
04:47 3 Reasons SAVA is a 100Xer — AD
09:22 3 Reasons — Evidence
19:39 3 Reasons — Value
30:17 Phones
#biotech
#financialfreedom
#investorsclub
Delusional !
Sign, Comment, and Share the Petition to Get Simufilam to Alzheimer’s Patients:
https://www.change.org/p/bring-simufilam-to-alzheimer-s-patients-as-soon-as-possible
Thx for the video and analysis. What I think it’s missing is the risk of another competitor solving the problem. Could you make an analysis of the competition and big pharmas? If they even solve it one year later they could easily try to stall sava just to overtake them.
BioVie Jumped 51% in February
The biotech company’s lead therapy is NE3107 for treating Alzheimer’s. The company said it has reached its revised enrollment target of 400 patients for its phase 3 trial for the therapy and hopes to have top-line results from the study in October. The purpose of the study will be to see whether NE3107 improves cognition on the Alzheimer’s Disease Assessment Scale-Cognitive.
Great summary!
Join the Small Caps Newsletter for early access to reports on two new small caps each month, plus the Discord and Book "Guide to Crushing the Market":
https://tendiesclub.substack.com/welcome
I like the like liking like thing, Joe. Keep it in.
3-11 years once diagnosed but the quality of life declines greater than 6% a year. Simufilium regains quality of life. No other drug has shown this.